Literature DB >> 12901705

Prevalence of epilepsy and associated health service utilization and mortality among patients with intellectual disability.

Christopher Ll Morgan1, Helen Baxter, Michael P Kerr.   

Abstract

We considered the prevalence of epilepsy and associated health service utilization for a population with intellectual disability. Registers for epilepsy and intellectual disability were created using a range of datasets. Of 1,595 people with an intellectual disability, 257 (16.1%) had epilepsy. Standardized activity ratios were 3.07 (95% CI 3.00 to 3.15), 2.03 (95% CI 1.94 to 2.11), and 3.09 (95% CI 2.78 to 3.41) for inpatients, outpatients, and accident and emergency, respectively. After excluding epilepsy-related inpatient admissions, we found the standardized activity ratio was 2.55 (2.48 to 2.62). Institutionalized patients were less likely to be admitted than were those in the community (standardized activity ratio = 0.63 (95% CI 0.54 to 0.73). Patients with intellectual disability and co-existing epilepsy used secondary care services more frequently than did those with intellectual disability only.

Entities:  

Mesh:

Year:  2003        PMID: 12901705     DOI: 10.1352/0895-8017(2003)108<293:POEAAH>2.0.CO;2

Source DB:  PubMed          Journal:  Am J Ment Retard        ISSN: 0895-8017


  12 in total

Review 1.  Health disparities between women with and without disabilities: a review of the research.

Authors:  Jennifer P Wisdom; Marjorie G McGee; Willi Horner-Johnson; Yvonne L Michael; Elizabeth Adams; Michelle Berlin
Journal:  Soc Work Public Health       Date:  2010-05

2.  Variation in health conditions among groups of adults with disabilities in primary care.

Authors:  Suzanne McDermott; Robert Moran; Tan Platt; Srikanth Dasari
Journal:  J Community Health       Date:  2006-06

Review 3.  Delivery of epilepsy care to adults with intellectual and developmental disabilities.

Authors:  Orrin Devinsky; Miya Asato; Peter Camfield; Eric Geller; Andres M Kanner; Seth Keller; Michael Kerr; Eric H Kossoff; Heather Lau; Sanjeev Kothare; Baldev K Singh; Elaine Wirrell
Journal:  Neurology       Date:  2015-09-30       Impact factor: 9.910

Review 4.  Non-pharmacological interventions for people with epilepsy and intellectual disabilities.

Authors:  Cerian F Jackson; Selina M Makin; Anthony G Marson; Michael Kerr
Journal:  Cochrane Database Syst Rev       Date:  2015-09-10

Review 5.  Clozapine for psychotic disorders in adults with intellectual disabilities.

Authors:  Muhammad Ayub; Khalid Saeed; Tariq A Munshi; Farooq Naeem
Journal:  Cochrane Database Syst Rev       Date:  2015-09-23

6.  Wordless intervention for epilepsy in learning disabilities (WIELD): study protocol for a randomized controlled feasibility trial.

Authors:  Marie-Anne Durand; Bob Gates; Georgina Parkes; Asif Zia; Karin Friedli; Garry Barton; Howard Ring; Linda Oostendorp; David Wellsted
Journal:  Trials       Date:  2014-11-20       Impact factor: 2.279

7.  Prevalence and incidence of physical health conditions in people with intellectual disability - a systematic review.

Authors:  Peiwen Liao; Claire Vajdic; Julian Trollor; Simone Reppermund
Journal:  PLoS One       Date:  2021-08-24       Impact factor: 3.240

8.  Aberrant sodium channel activity in the complex seizure disorder of Celf4 mutant mice.

Authors:  Wenzhi Sun; Jacy L Wagnon; Connie L Mahaffey; Michael Briese; Jernej Ule; Wayne N Frankel
Journal:  J Physiol       Date:  2012-10-22       Impact factor: 5.182

9.  CELF4 regulates translation and local abundance of a vast set of mRNAs, including genes associated with regulation of synaptic function.

Authors:  Jacy L Wagnon; Michael Briese; Wenzhi Sun; Connie L Mahaffey; Tomaž Curk; Gregor Rot; Jernej Ule; Wayne N Frankel
Journal:  PLoS Genet       Date:  2012-11-29       Impact factor: 5.917

Review 10.  Pharmacological interventions for epilepsy in people with intellectual disabilities.

Authors:  Cerian F Jackson; Selina M Makin; Anthony G Marson; Michael Kerr
Journal:  Cochrane Database Syst Rev       Date:  2015-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.